Influence of on-going treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke.

Many patients who receive intravenous (i.v.) recombinant tissue-plasminogen activator (rt-PA) for acute cerebral ischemia were under angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) at stroke onset. ACE-Is and ARBs have neuroprotective properties in animal models.

• Publication date: May 2018
• Journal: Journal of neurology
• Publication date: Gilliot S, Sibon I, Mas JL, Moulin T, Béjot Y, Cordonnier C, Giroud M, Odou P, Bordet R, Vivien D, Leys D,
• ISSN: 1432-1459